BiDil raises questions about race as a marker.
Branca
Malorye Allison
MA
D015415:Biomarkers / Q000378:metabolism*; D044383:Black People / Q000235:genetics; D002986:Clinical Trials as Topic / Q000191:economics / Q000379:methods; D054067:Dihydropyrimidine Dehydrogenase Deficiency; D042943:Dihydrouracil Dehydrogenase (NADP) / Q000378:metabolism / Q000494:pharmacology; D017277:Drug Approval / Q000331:legislation & jurisprudence / Q000379:methods; D004338:Drug Combinations; D004347:Drug Interactions; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000235:genetics / Q000627:therapeutic use; D000069347:Erlotinib Hydrochloride; D005472:Fluorouracil / Q000378:metabolism / Q000627:therapeutic use; D000077156:Gefitinib; D006333:Heart Failure / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality; D006801:Humans; D006830:Hydralazine / Q000737:chemistry / Q000627:therapeutic use*; D007547:Isosorbide / Q000737:chemistry / Q000627:therapeutic use*; D008875:Middle Aged; D009154:Mutation / Q000235:genetics; D009316:National Institutes of Health (U.S.); D011110:Polymorphism, Genetic; D011799:Quinazolines / Q000627:therapeutic use; D012307:Risk Factors; D012959:Socioeconomic Factors; D016896:Treatment Outcome; D014481:United States; D014498:Uracil / Q000378:metabolism; D044465:White People / Q000235:genetics; D001741:Black or African American
D015415:Biomarkers; D004338:Drug Combinations; D011799:Quinazolines; D006830:Hydralazine; D014498:Uracil; D000069347:Erlotinib Hydrochloride; D042943:Dihydrouracil Dehydrogenase (NADP); D066246:ErbB Receptors; D000077156:Gefitinib; D005472:Fluorouracil; D007547:Isosorbide